Is fixed combination therapy appropriate for initial hypertension treatment?

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Single-drug therapy for hypertension frequently fails to achieve target blood pressure (BP) and reduce cardiovascular events.
• Fixed-dose combination products for hypertension have become increasingly common, with 14 approved in the U.S. since 1993.

Purpose of the Study:

• To evaluate the efficacy and advantages of fixed-dose combination therapy for hypertension.
• To identify patient populations most likely to benefit from initial combination therapy.

Main Methods:

• Review of clinical trials and Food and Drug Administration (FDA) indications for fixed-dose combination hypertension products.
• Analysis of requirements for initial therapy indication, including safety, efficacy, additive BP lowering, and synergy.
• Identification of patient profiles and comorbidities (e.g., high BP, target organ damage, diabetes) benefiting from combination therapy.

Main Results:

• Only five fixed-dose combination products are FDA-indicated for initial hypertension therapy, all including a diuretic.
• Initial combination therapy offers advantages such as greater BP reduction, improved adherence, fewer side effects, and lower cost.
• Patients with higher initial BP (e.g., >160/100 mm Hg) or specific comorbidities are prime candidates for initial combination therapy.

Conclusions:

• Fixed-dose combination therapy, particularly with an angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist plus a diuretic or calcium channel blocker, is effective for achieving BP goals.
• Further research is exploring combinations addressing metabolic syndrome components often accompanying hypertension.